Table I.
Association of clinicopathological background with initial cancer between patients in the HT group and those in the no HT group.
| Clincopathological criteria | HT group (n=41) | No HT group (n=17) | P-value |
|---|---|---|---|
| Age at diagnosis, years | |||
| <50 | 25 | 8 | 0.390 |
| ≥50 | 16 | 9 | |
| T-stage | |||
| T1 | 24 | 13 | 0.241 |
| T2-4 | 17 | 4 | |
| Lymph node status | |||
| Absence | 34 | 15 | 1.000 |
| Presence | 7 | 2 | |
| ER status | |||
| Positive | 41 | 6 | 0.001 |
| Negative | 0 | 9 | |
| N/A | 2 | ||
| PgR status | |||
| Positive | 39 | 6 | 0.001 |
| Negative | 2 | 9 | |
| N/A | 2 | ||
| HER2 status | |||
| Positive | 6 | 4 | 0.438 |
| Negative | 33 | 11 | |
| N/A | 2 | 2 | |
| Ki67 status (%) | |||
| <14 | 35 | 14 | 1.000 |
| ≥14 | 4 | 1 | |
| N/A | 2 | 2 | |
| Subtype | |||
| Luminal A | 28 | 5 | |
| Luminal B | 5 | 0 | |
| HER2 enriched | 6 | 4 | |
| Basal like | 0 | 6 | |
| N/A | 2 | 2 | |
| HT | |||
| TAM (2 years) | 19 | – | – |
| TAM (5–10 years) | 16 | – | |
| Switch from | 1 | – | |
| TAM to AI | |||
| AI (5 years) | 5 | – | |
| Chemotherapy | |||
| Yes | 21 | 7 | 0.570 |
| No | 20 | 10 | |
| Trastuzumab | |||
| Yes | 2 | 2 | 0.573 |
| No | 39 | 15 | |
HT group, patients who received hormone therapy for the initial cancer; no HT group, patients who did not receive hormone therapy for the initial cancer; ER, oestrogen receptor; PgR, progesterone-receptor; HER2, human epidermal growth factor receptor 2; TAM, tamoxifen; AI, aromatase inhibitor; N/A, not available.